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DOI 10.1016/j.ccr.2012.02.010SUMMARYAmplification of the MYCN oncogene in childhood neuroblastoma is often accompanied by mutational
activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic cooperation. We generated a
transgenic zebrafish model of neuroblastoma in which MYCN-induced tumors arise from a subpopulation
of neuroblasts that migrate into the adrenal medulla analog following organogenesis. Coexpression of
activatedALKwithMYCN in thismodel triples the disease penetrance andmarkedly accelerates tumor onset.
MYCN overexpression induces adrenal sympathetic neuroblast hyperplasia, blocks chromaffin cell differen-
tiation, and ultimately triggers a developmentally-timed apoptotic response in the hyperplastic sympathoa-
drenal cells. Coexpression of activatedALKwithMYCN provides prosurvival signals that block this apoptotic
response and allow continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus
promoting progression to neuroblastoma.INTRODUCTION
Neuroblastoma is a childhood solid tumor that arises in the
peripheral sympathetic nervous system (PSNS), typically in the
adrenal medulla or paraspinal ganglia, during embryogenesis
(Brodeur, 2003; Maris, 2010). When disseminated at diagnosis
in older children, the disease carries a very poor prognosis
despite the use of intensive therapies. Amplification of the
MYCN oncogene is found in tumor cells from 20% of neuro-
blastoma patients and is themost reliable marker of a poor prog-Significance
Neuroblastoma is an important developmental tumor arising in
for 10% of cancer-related deaths in childhood. The ALK rece
primary neuroblastomas, but the mechanisms through which
neuroblastoma pathogenesis remain unclear. By generating
MYCN and activated ALK in the fish analog of the adrenal med
thetic neuroblast hyperplasia, which is mitigated by a develo
neuroblast apoptosis at this critical time in development, estab
these two oncoproteins in the pathogenesis of neuroblastoma
362 Cancer Cell 21, 362–373, March 20, 2012 ª2012 Elsevier Inc.nosis (Brodeur, 2003; Maris et al., 2007). Overexpression of
MYCN in the PSNS of transgenic mice, using the rat tyrosine
hydroxylase (TH) promoter, results in tumors that closely
resemble human neuroblastoma arising in the sympathetic
ganglia (Chesler and Weiss, 2011; Weiss et al., 1997), indicating
that aberrant expression ofMYCN promotes the development of
this tumor in vivo.
The anaplastic lymphoma kinase (ALK) gene encodes a
receptor tyrosine kinase that is normally expressed at high levels
in the nervous system and was originally identified as a fusionthe peripheral sympathetic nervous system, which accounts
ptor tyrosine kinase is mutationally activated in a subset of
ALK signaling cooperates with MYCN overexpression in
a transgenic zebrafish model that overexpresses human
ulla, we now show that upregulatedMYCNmediates sympa-
pmentally-timed apoptotic response. Activated ALK blocks
lishing amechanism for the synergistic relationship between
.
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MYCN and ALK in Neuroblastoma Pathogenesisprotein with nucleophosmin in cases of anaplastic large cell
lymphoma (Morris et al., 1994). Activation of ALK can regulate
cellular proliferation, differentiation and apoptosis via a number
of different signaling pathways, including PI3K/AKT, RAS/
MAPK, and STAT3, but its precise physiologic role remains
elusive (Chiarle et al., 2008; Palmer et al., 2009). Recently, we
and others reported that amplification of the ALK gene occurs
only inMYCN-amplified primary neuroblastomas and that within
this group15% of cases have ALK amplification (George et al.,
2008; Mosse´ et al., 2008). Activating ALK mutations were also
identified in both familial and sporadic neuroblastoma cases,
including but not limited to a subset with MYCN amplification,
further implicating this kinase in neuroblastoma pathogenesis
(Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al.,
2008; Mosse´ et al., 2008). Mechanisms through which signaling
by aberrantly activated ALK cooperates with MYCN overexpres-
sion to enhance neuroblastoma development remain undefined,
posing amajor obstacle to the development of effective targeted
treatments for this devastating disease.
We have generated a transgenic zebrafish model in which
overexpression of human MYCN in the PSNS induces tumors
in the fish analog of the adrenal medulla that closely resemble
human neuroblastoma. Using this model system, we undertook
studies to exploremechanistically the interaction betweenmuta-
tionally activated ALK and MYCN overexpression during neuro-
blastoma pathogenesis in the PSNS.
RESULTS
Transgenic EGFP Expression in the PSNS
We first isolated a 5.2 kb promoter fragment upstream of the
coding sequence of the zebrafish dopamine-b-hydroxylase
gene (dbh), which encodes the rate-limiting enzyme for
noradrenalin synthesis. This fragment was used to drive expres-
sion of enhanced green fluorescent protein (EGFP) in a stable ze-
brafish transgenic line, Tg(dbh:EGFP), designated DbH in this
article. In juvenile and adult transgenic zebrafish, EGFP was
specifically expressed by sympathetic neurons of the superior
cervical ganglia (Figures 1A–1C), the first sympathetic ganglion
to develop in early embryogenesis, and by each sequential
segmental ganglion of the sympathetic chain (Figures 1A, 1B,
and 1D). EGFP was also expressed by sympathoadrenal cells
of the interrenal gland (Figures 1A, 1B, and 1E), the zebrafish
equivalent of the human adrenal gland (Hsu et al., 2003). In the
interrenal gland, the EGFP-expressing cells can be visualized
within a discrete region in the ventral aspect of the head kidney,
intermixed with adrenal cortical cells that are TH- and EGFP-
negative (Figure 1E). The specificity of EGFP expression for sym-
pathoadrenal cells when driven by the dbh promoter fragment is
demonstrated by coexpression of endogenous TH (Figures 1C–
1E), another enzyme expressed by sympathetic neurons and
chromaffin cells (An et al., 2002; O’Brien et al., 2004).
Zebrafish Expressing MYCN Develop Neuroblastoma
Using a coinjection strategy (Langenau et al., 2008), we gener-
ated a stable transgenic zebrafish line, Tg(dbh:EGFP-MYCN),
designated MYCN in this article, that overexpresses the human
MYCN gene fused to EGFP under control of the dbh promoter.
In MYCN transgenic fish the expansion of cells expressingEGFP as tumors developed was readily detectable in living fish
by immunofluorescence microscopy (Figure 2A). EGFP+ tumor
masses were found in the anterior abdomen, corresponding to
the interrenal gland, and were composed of small, undifferenti-
ated, round-tumor cells with hyperchromatic nuclei, often form-
ing nests (Figure 2B). Tumor cells were strongly immunoreactive
for TH and the pan-neuronal markers Hu and Synaptophysin
(Figure 2C), indicating their PSNS-related neuronal origin (Gould
et al., 1986; Marusich et al., 1994; Teitelman et al., 1979). Normal
interrenal chromaffin cells also expressed TH, but not Hu or Syn-
aptophysin (Figure 2C), indicating that the neuroblastomas arose
from sympathetic neuroblast precursors and not chromaffin
cells, as is the case in human neuroblastoma (Figure 2E).
Neuroblastoma is frequently considered in the differential
diagnosis of malignant small round-cell tumors of childhood,
and electron microscopy is a helpful tool for distinguishing
among these malignancies. A diagnosis of neuroblastoma can
be established ultrastructurally by demonstrating the presence
of neurosecretory granules within the cytoplasm or cytoplasmic
processes of tumor cells (Figure 2E) (Mierau et al., 1998). These
neurosecretory granules were evident in the tumors we identified
in the zebrafish (Figure 2D), strengthening their association with
childhood neuroblastoma. The histopathological, immunohisto-
chemical and ultrastructural features of neuroblastoma are
shown in Figure 2E, to illustrate their similarities with those of
neuroblastomas induced by MYCN overexpression in zebrafish
(Figures 2B–2D) (Hoshi et al., 2008; Mierau et al., 1998; Molenaar
et al., 1990; Taxy, 1980; Torno´czky et al., 2007). These findings
support our use of this model to investigate activated ALK as
a contributor to MYCN-driven tumorigenesis.
ALK Accelerates MYCN-Induced Neuroblastoma
We and others have implicated activating mutations of ALK in
the pathogenesis of neuroblastoma, including cases that also
show MYCN amplification (De Brouwer et al., 2010; George
et al., 2008; Mosse´ et al., 2008). To address whether ALK and
MYCN genetically interact during neuroblastoma induction, we
generated a second stable transgenic zebrafish line that
expresses the human ALK gene harboring the F1174Lmutation,
one of the most prevalent somatic activating mutations found
in neuroblastoma patients and human cell lines (Chen et al.,
2008; George et al., 2008). The dbh:EGFP and dbh:ALKF1174L
constructs were coinjected into zebrafish embryos at the one-
cell stage to generate a transgenic line expressing both the
EGFP and activated ALK transgenes, Tg(dbh:EGFP;dbh:
ALKF1174L), designated ALK in this article. EGFP was specifi-
cally expressed by sympathoadrenal cells in the interrenal
gland of the ALK transgenic fish at 5 weeks postfertilization
(wpf), and ALK was coexpressed with EGFP by the same cells
(Figure S1A available online). This transgenic line was bred to
the MYCN heterozygous transgenic line, and the offspring
were monitored for evidence of tumors. All of the expected
genotypes were represented in the offspring of this cross: (1)
MYCN; (2) ALK; (3) MYCN;ALK; and (4) wild-type (WT) AB fish
lacking either transgene. A tumorwatchwas performed on a total
of 1,156 sorted offspring. The fish were isolated in individual
tanks as soon as tumors appeared; and were sacrificed for
molecular and pathologic analyses when there was evidence
of tumor progression.Cancer Cell 21, 362–373, March 20, 2012 ª2012 Elsevier Inc. 363
Figure 1. Transgenic Gene Expression in the Sympathetic Neurons and the Interrenal Gland
(A) Left: Schematic of a transverse section illustrating zebrafish anatomical structures, dorsal upward. Right: Schematic of a sagittal section illustrating zebrafish
anatomical structures, anterior to left.
(B) EGFP expression (green) in the zebrafish chain of sympathetic ganglia (arrowheads), the IRG (arrow), andmedulla oblongata (asterisk) at 3 wpf. Lateral view of
confocal-brightfield image, anterior to left. The magnified view of the boxed region is shown on the right. Scale bar represents 500 mm.
(C) EGFP is coexpressed with TH in the SCG at 6 wpf (sagittal section); TH coexpression is indicated in red. Scale bar represents 20 mm.
(D) EGFP is coexpressed with TH in the chain of sympathetic ganglia at 6 wpf (transverse section). TH coexpression is indicated in red. Scale bar
represents 20 mm.
(E) EGFP is coexpressed with TH in the IRG at 8months postfertilization (mpf) (sagittal section). TH coexpression is indicated in red. Scale bar represents 100 mm.
Ao, aorta; Cb, cerebellum; Chfn, chromaffin cells; E, esophagus; G, gill; H, heart; HK, head kidney; I, intestine; IRG, interregnal gland; KB, kidney body; L, liver; Me,
medulla; Nc, notochord; SB, swim bladder; SC, spinal cord; SCG, superior cervical ganglion; Sym.C, sympathetic chain. See also Figure S1.
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had the compound transgenic genotype,MYCN;ALK (Figure 3A).
The expression of MYCN and ALK proteins and ALK RNA was
confirmed in the tumors of these compound transgenic fish by
immunohistochemical and RT-PCR analyses, respectively
(Figures S1B and S1C). Tumors continued to arise after 9 weeks
of age in both the MYCN-only and the MYCN;ALK compound
transgenic lines, but their rate of induction was much higher in
the latter group (Figure 3A). Tumor penetrance in the MYCN;ALK
compound transgenic fish was also much higher: 55.6% versus
17.3% for the MYCN transgenic fish (p < 0.0001; Figure 3A).
Although germlinemutations ofALK cause hereditary neuroblas-
toma (Mosse´ et al., 2008), tumors did not develop in fish ex-
pressing this transgene alone over the 6-month monitoring364 Cancer Cell 21, 362–373, March 20, 2012 ª2012 Elsevier Inc.period (Figure 3A). Tumors in the compound transgenic fish
arose in the interrenal gland, as did those in the MYCN fish,
and these tumors were comparable histologically, immunohisto-
chemically, and ultrastructurally (Figure S2) to human neuroblas-
toma (Figure 2E).
To control for possible founder effects in our transgenic lines,
and to examine whether overexpression of wild-type ALK
(ALKWT) as well as mutationally activated ALK could collaborate
with MYCN in neuroblastoma pathogenesis, we overexpressed
either activated human ALK or human ALKWT in MYCN fish.
For this experiment, we coinjected the following constructs
into the one-cell stage ofMYCN transgenic and control embryos:
(1) dbh-ALKF1174Lwith dbh-mCherry; (2) dbh-ALKWTwith dbh-
mCherry; or (3) dbh-mCherry alone. We have shown that this
Figure 2. Neuroblastomas Arise in MYCN-
Expressing Transgenic Zebrafish
(A) Top: DbH fish. Bottom: MYCN fish with EGFP-
expressing tumor (arrow) at 32 weeks postfertilization
(wpf). Scale bar represents 1 mm.
(B) Top: H&E-stained sagittal sections of DbH fish. Boxes
indicate the SCG and the IRG, and are magnified in the
right panels. Bottom: H&E-stained sagittal sections of
MYCN fish with neuroblastic tumors. Boxes indicate the
SCG and the IRG and are magnified in the right panels.
Arrows indicate SCG neurons. The majority of tumors
arise in the IRG of MYCN fish, although as seen in this
example, tumor cells in the SCG were occasionally
observed in individual fish that also had tumors in the
IRG. G, gill; L, liver; I, intestine; IRG, interregnal gland;
SCG, superior cervical ganglion; T, testis. Scale bars
represent 50 mm.
(C) Top: Sagittal sections through the interregnal gland of
DbH fish. Chromaffin cells of the interregnal gland
express TH (arrows). Bottom: Sagittal sections through
the interregnal gland of a MYCN fish with EGFP-
expressing tumor. Cells throughout the tumor in the in-
terregnal gland express TH, Synaptophysin (Synap), and
Hu. Scale bar represents 100 mm.
(D) Electron microscopy (EM) reveals neurosecretory
granules in the MYCN-expressing tumors (arrows). Scale
bar represents 500 nm.
(E) Pathological, immunohistochemical, and ultrastruc-
tural analyses of a human neuroblastoma. Arrows point
to neurosecretory granules. Scale bars represent 500 mm
(left panel), 100 mm (middle panels), and 2 mm (right
panel), respectively. See also Figure S2.
Cancer Cell
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pression of the two coinjected transgenes asmosaics in a subset
of cells in50% of the injected embryos (Langenau et al., 2008).
Thus, the expression of mCherry served as a marker for the co-
expression of ALK in tissues of the mosaic primary injected
animals. When these animals were monitored for the tumor
onset, neuroblastomas were not observed in any of the siblings
that did not inherit the MYCN transgene and were injected with
either the ALKWT or ALKF1174L transgenes, emphasizing that
overexpression of MYCN is required for tumorigenesis in this
model. Eight tumors arose by 9 wpf in the MYCN fish coinjected
with dbh-ALKF1174L and dbh-mCherry (Figures 3B and S3A),
whereas none were observed by 9 wpf in the MYCN line coin-
jected with dbh-ALKWT and dbh-mCherry (p = 0.002; Figures
3B and S3B) or with dbh-mCherry alone (p = 0.007; Figures 3B
and S3C). In addition, four tumors in the MYCN line coinjected
with dbh-ALKWT and dbh-mCherry and five tumors in the
MYCN line injected with dbh-mCherry alone were identified after
11 wpf (Figure 3B), similar to the time of tumor onset in the unin-
jectedMYCN line (Figure 3A). These findings show that activated
ALK cooperates with MYCN overexpression to accelerate the
onset of neuroblastoma, regardless of the integration site in indi-
vidual mosaic animals, and that overexpression of ALKWT at the
levels driven by the dbh promoter does not appear to collaborate
with MYCN to induce neuroblastoma in this model system.MYCN-Induced Loss of Sympathoadrenal Cells
To investigate the cellular basis for MYCN-induced neuroblas-
toma and its modification by constitutively activated ALK, we
examined the development of sympathoadrenal cells in (1)
DbH; (2) MYCN; (3) ALK; and (4) MYCN;ALK transgenic fish
during the embryonic and larval stages. During normal develop-
ment, PSNS cells arise from the neural crest and migrate
ventrally to locations adjacent to the dorsal aorta (Huber,
2006). After forming the superior cervical ganglia, a subset of
sympathoadrenal cells migrate further to invade the meso-
nephros and differentiate to form chromaffin cells in the inter-
renal gland (An et al., 2002; Huber, 2006; Stewart et al., 2004).
We identified cells of the developing superior cervical ganglia
at 80 hr postfertilization (hpf) in living DbH transgenic fish and
in whole-mount in situ hybridization preparations with dbh- and
th- riboprobes (Figure 4A), indicating that EGFP expression in
the developing embryonic PSNS of this transgenic line recapitu-
lates the normal endogenous expression patterns of dbh and th
(Figure 4A). By 80 hpf, EGFP was apparent in the superior
cervical ganglia, as well as in non-PSNS dopaminergic neurons,
such as themedulla oblongata and cranial ganglia (Figure 4A). By
contrast, most MYCN transgenic embryos (80%) failed to
express a detectable level of EGFP fused to human MYCN in
the superior cervical ganglia at 80 hpf, even though the fusion
protein was clearly expressed in non-PSNS tissues (Figure 4B),Cancer Cell 21, 362–373, March 20, 2012 ª2012 Elsevier Inc. 365
Figure 3. Activated ALK Accelerates Disease Onset and Increases
the Penetrance of MYCN-Induced Neuroblastoma
(A) Cumulative frequency of neuroblastoma in stable transgenic zebrafish by
Kaplan-Meier analysis. ALKmut represents stable transgenic fish expressing
the ALK (F1174L) transgene. WT, wild-type.
(B) Onset of neuroblastoma in MYCN transgenic fish or wild-type (WT) fish as
mosaics coinjected with the following DNA constructs: (1) dbh-ALKF1174L
and dbh-mCherry (mosaic ALKmut); (2) dbh-ALKWT and dbh-mCherry
(mosaic ALKWT); or (3) dbh-mCherry alone. The difference between tumor
onset by 9 wpf in the MYCN fish coinjected with dbh-ALKF1174L and dbh-
mCherry (MYCN; mosaic ALKmut) and that in the MYCN line coinjected with
dbh-ALKWT and dbh-mCherry (MYCN;mosaic ALKWT) or dbh-mCherry alone
(MYCN) is significant at p = 0.002 and p = 0.007, respectively, with two-tailed
Fisher exact test. See also Figure S3.
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366 Cancer Cell 21, 362–373, March 20, 2012 ª2012 Elsevier Inc.and in most animals, the absence of detectable sympathoadre-
nal cells persisted through 10 dpf (Figure S4C). The lack of EGFP
expression is consistent with the markedly reduced numbers of
sympathoadrenal cells in MYCN embryos indicated by the loss
of cells with endogenous th and dbh RNA expression by
whole-mount in situ hybridization (Figures 4B versus 4A).
Because th and dbh are markers for differentiated sympathoa-
drenal cells, the absence of cells expressing EGFP-MYCN under
control of the dbh promoter could reflect either MYCN-induced
apoptosis or an arrest in sympathoadrenal progenitor cell
differentiation.
To distinguish between these possibilities, we first performed
TUNEL and anti-activated Caspase-3 staining on sections of 36,
51, and 72 hpf MYCN versus DbH transgenic fish. We found no
evidence of TUNEL- or anti-activated Caspase-3-positive cells
in the superior cervical ganglia or regions where sympathoadre-
nal cells would be expected to form (Figure S5; data not shown),
suggesting that the absence of detectable sympathoadrenal
cells is not due to cell death, but rather to a failure to initiate
the PSNS developmental program at this early time in develop-
ment. To test this possibility, we performed whole-mount
in situ hybridization at 54 hpf and 80 hpf for expression of the
phox2b, zash1a, and AP-2 alpha (tfap2a) genes, which encode
transcription factors required for sympathoadrenal cell specifi-
cation and maintenance (Figure 5) (Guillemot et al., 1993; Lucas
et al., 2006; Pattyn et al., 1999). Each of these sympathoadrenal
cell progenitor markers was readily detectable in the superior
cervical ganglia region of control embryos, but undetectable in
MYCN transgenic embryos at these stages, indicating that spec-
ification of the earliest identifiable sympathoadrenal cell progen-
itors was blocked by expression of the EGFP-MYCN fusion
gene. The suppression of sympathoadrenal cell development
by EGFP-MYCN appears to be tissue-specific, because expres-
sion of the EGFP-MYCN by non-PSNS dopaminergic neuronal
cells in these embryos was largely unaffected, including expres-
sion by cells of the locus coeruleus, medulla oblongata, and
cranial ganglia (Figures 4B versus 4A and S4C).
To investigate the possibility that neuroblastoma might arise
from residual EGFP-MYCN+ sympathoadrenal cells that can
be identified at 3 dpf in 20% of the transgenic embryos, we
analyzed these embryos in more detail at 5 dpf. At this time,
neurons of the superior cervical ganglia in control DbH trans-
genic fish express EGFP and are both TH+ and Hu+ (arrows in
Figure S4A), whereas chromaffin cells lose Hu expression as
they differentiate into chromaffin cells, reflecting a loss of their
neuronal phenotype (arrowheads in Figure S4A). Interestingly,
the small populations of EGFP+ cells observed in the superior
cervical ganglia of MYCN animals were heterogeneous in their
immunoreactivity patterns, including cells that were TH+/Hu
(arrowheads in Figure S4B), TH/Hu (double arrowheads in
Figure S4B), or TH+/Hu+ (data not shown). However, these
residual cells did not appear to contribute to neuroblastoma
development, as there was no difference in the time of disease
onset in the 20% of fish that had small numbers of residual cells
at 5 dpf compared to the majority of MYCN transgenic fish,
which lacked detectable cells in the superior cervical ganglia
(Table S1).
Expression of mutant ALK F1174L in ALK transgenic fish did
not affect the development of sympathoadrenal cells, as shown
Figure 4. MYCN Expression Causes Sympathoa-
drenal Cell Loss
(A) DbH transgenic line. Oblique views of dbh RNA
expression (left panels); lateral views of EGFP expression
in merged confocal-brightfield images (middle panels);
dorsal views of th RNA expression (right panels). Arrows
point to the SCG, and arrowheads point to the CG. Scale
bar represents 100 mm.
(B) MYCN transgenic line. MYCN expression causes loss
of cells in the SCG (arrows). Scale bar represents 100 mm.
(C) ALK transgenic line. ALK expression does not interfere
with the SCG development (arrows). Scale bar represents
100 mm.
(D) MYCN;ALK transgenic line. Loss of cells in the SCG is
not rescued by activated ALK expression (arrows). Scale
bar represents 100 mm. AAC, arch-associated catechol-
aminergic neurons; CG (arrowheads), cranial ganglia; DA,
diencephalic dopaminergic neurons; e, ear; LC, locus
coeruleus; MO, medulla oblongata; r, retina; SCG, supe-
rior cervical ganglion. See also Figure S4 and Table S1.
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(Figures 4C and S4C). Furthermore, the expression of activated
ALK in the presence ofMYCN in MYCN;ALK transgenic embryos
did not rescue the loss of sympathoadrenal cells observed in the
MYCN transgenic embryos (Figures 4D and S4C). Thus,
although activated ALK clearly cooperates with MYCN in tumor-
igenesis, this interplay does not depend on any ability of ALK to
reverse the pronounced MYCN-induced suppression of sympa-
thoadrenal cell development during early embryonic and larval
stages.
Hyperplasic Hu+ Cells in the Interrenal Gland
Analysis of the PSNS during the first 10 days of life in MYCN
transgenic zebrafish revealed the profound capacity of high level
of MYCN to suppress the development of sympathoadrenal
cells, but did not provide any insight into why these transgenic
fish developed neuroblastoma. Because the first tumors arose
in MYCN;ALK transgenic fish between 5–7 wpf, we examined
the interrenal gland of MYCN transgenic zebrafish beginning at
3 wpf to identify the cells that give rise to neuroblastoma. In
DbH control animals, we observed GFP+/Hu+/TH+ neuroblast
cells in both the mediolateral (Figure 6A) and lateral regions of
the developing interrenal gland (Figure S6). The number of Hu+Cancer Cell 21, 3neuroblasts quantified from sections through
both interrenal gland regions remained low
between 3–7 wpf (Figure 6B); Hu+ cell numbers
in ALK transgenic fish were comparable to
those in controls (Figure 6B). By contrast, the
numbers of Hu+ neuroblasts were significantly
increased in MYCN transgenic fish, as
compared to those in controls at 3 wpf (Fig-
ure 6B, p = 0.03). In 9 of 16 MYCN transgenic
fish examined, the numbers of Hu+ neuroblasts
were markedly increased at 5 wpf (Figures 6A
and 6B, p = 0.004). However, at 7 wpf, 11 of
16 MYCN fish lacked detectable Hu+ neuro-
blasts in the interrenal gland (Figure 6B), indi-
cating that during this 2-week period these cellswere either eliminated or had differentiated, thus losing their
expression of the neuronal marker Hu. In MYCN;ALK compound
transgenic fish the numbers of Hu+ cells also increased during
the 3- to 5-week period, but in contrast to transgenic fish ex-
pressing MYCN alone, the Hu+ cell numbers continued to
increase in 6 of 12 fish at 7 wpf (Figure 6B, p = 0.03). Thus,
Hu+ cells continue to expand in only a small fraction of trans-
genic animals expressing MYCN alone after 5 wpf, whereas
a much higher fraction of the double transgenic MYCN;ALK
animals showed progressive expansion of Hu+ cells, mirroring
the much higher fraction of these animals that develop fully
transformed neuroblastoma (Figure 3A).
To assess the effects ofMYCN and activated ALK expression
on the differentiation of Hu+, TH+ neuroblast into Hu, TH+
adrenal chromaffin cells, we quantified the numbers of Hu,
GFP+ cells within the interrenal gland of each of the zebrafish
lines over time. We found increasing numbers of these cells
between 3–7 wpf in both control DbH and ALK transgenic zebra-
fish, indicating the differentiation of the Hu+ neuroblast precur-
sors into chromaffin cells (Figures 7A–7C). By contrast, the
Hu, GFP+ chromaffin cells did not increase normally and re-
mained at very low levels between 3–7 wpf in MYCN-overex-
pressing fish relative to control animals, regardless of whether62–373, March 20, 2012 ª2012 Elsevier Inc. 367
Figure 5. Expression of Early Sympathoadrenal
Markers Is Absent in MYCN Transgenic Embryos
during Early Development
(A and B) Top panels: DbH; lower panels: MYCN trans-
genic fish. Expression of sympathoadrenal cell markers at
54 hpf (A) and 80 hpf (B). The magnified view of the boxed
region is shown on the right. Arrows point to the superior
cervical ganglion. Scale bars represent 50 mm (left panels)
and 100 mm (right panels, magnified view).
(C) Diagram of the genetic interactions of sympathoa-
drenal genes during early development. Arrows indicate
the activation of target genes. Curved arrows indicate
positive feedback regulation. See also Figure S5.
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7C). At 7 wpf, we identified two MYCN transgenic fish and two
MYCN;ALK fish with some expansion of Hu/TH+ chromaffin
cells (Figure 7C). Thus, in a small subset ofMYCN-overexpress-
ing fish, the sympathoadrenal cells manage to differentiate, lose
the Hu neuronal marker and expand at 7 weeks of age despite
activated ALK overexpression. The chromaffin cell expansion
seems to be self-limited, because all of the tumors that arise in
these fish express the Hu pan-neuronal marker (Figures 2C
and S2C).
To determine whether the loss of Hu+ cells in the transgenic
fish expressing MYCN alone between 5–7 wpf was due to
apoptotic cell death, we assessed the expression of activated
Caspase-3 as an indicator of apoptotic cell death. An important
difference was observed at 5.5 wpf: transgenic fish expressing
MYCN alone showed significant numbers of apoptotic cells
coexpressing Hu and activated Caspase-3 (Figures 8B, 8C
and S7C), providing the basis for the profound loss of these cells
by 7 wpf. By contrast, in MYCN;ALK transgenic fish, we rarely
observed apoptotic cells expressing both Hu and activated
Caspase-3 (Figures 8B, 8C and S7D), consistent with the
continued increase in Hu+ cell numbers at 7 wpf in this group
(Figure 6B). Neuroblastomas that develop in MYCN transgenic
animals coexpress GFP, TH, and Hu, regardless of whether368 Cancer Cell 21, 362–373, March 20, 2012 ª2012 Elsevier Inc.the animals also express the activated ALK
transgene. Thus, the expanding neuroblast
cell populations that we identified at 7 wpf in
MYCN transgenic animals appear to give rise
to fully transformed tumors a few weeks later,
and a fraction of the fish with these hyperplastic
precursors was markedly increased by coex-
pression of activated ALK, accounting for the
increased penetrance of neuroblastoma in the
compound transgenic line (Figure 3A). Taken
together, these findings indicate that overex-
pression of MYCN prevents the differentiation
of neuroblast precursors into adrenal chro-
maffin cells, and induces a developmentally-
timed apoptotic response at 5.5 wpf in most
MYCN transgenic fish. However, concomitant
expression of activated ALK in these cells
promotes cell survival without altering the
MYCN-induced block in differentiation, result-
ing in the continued accumulation of Hu+ neu-roblasts that culminates in the development of highly penetrant,
fully transformed neuroblastoma.
DISCUSSION
Early in the embryogenesis of our transgenic zebrafish, MYCN
overexpression results in a profound loss of neural crest-derived
cells within the sympathoadrenal cell lineage. Nevertheless,
these animals can develop neuroblastoma, and both the onset
and penetrance of the disease are markedly enhanced by
coexpression of a transgene encoding the activated ALK
receptor tyrosine kinase. Thus, our zebrafish model clearly
demonstrates a synergistic relationship between these two
genes in neuroblastoma pathogenesis. Using multiparameter
confocal microscopy and immunohistochemistry to examine
embryos throughout early development, we show that MYCN-
induced neuroblastoma does not arise from the earliest cells
populating the superior cervical ganglia (3–6 dpf), but rather
from neuroblasts that migrate into the interrenal gland later in
development (21 dpf), after the kidney has developed.
The interrenal gland is the zebrafish equivalent of the human
adrenal gland, and sympathoadrenal precursors in the interrenal
gland coexpress neuronal-specific Hu proteins and the cate-
cholaminergic enzymes TH and Dbh. The interrenal gland origin
Figure 6. MYCN Causes Hu+ Cell Hyperplasia in the Interrenal Gland
(A) Sagittal sections through the interrenal gland in DbH (top panels), MYCN (middle panels), and MYCN;ALK (lower panels) transgenic fish at 5wpf (dorsal up,
anterior left). EGFP, green; Hu, magenta; TH, red. Representative sections through the interrenal gland in DbH fish contain three to five GFP+/Hu+/TH+
sympathetic neuroblasts (arrows) and many GFP+/Hu/TH+ chromaffin cells (arrowheads). Hu+ cell numbers increase in MYCN and MYCN;ALK fish (brackets),
and can be GFP+ and TH+. Dotted lines indicate the head kidney (HK) boundary. Scale bar represents 20 mm.
(B) Numbers of Hu+ interrenal gland cells in DbH, ALK,MYCN, andMYCN;ALK transgenic fish at 3, 5, and 7weeks.Means of Hu+ cell numberswere compared by
the two-tailed Wilcoxon signed-rank test. See also Figure S6.
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lary site of origin observed in 50% of the children with this
tumor (Janoueix-Lerosey et al., 2010), in contrast to the murine
MYCN transgenic model, where tumors arise from hyperplastic
neuroblasts predominately in the sympathetic cervical ganglia
complex and the superior cervical ganglia (Alam et al., 2009;
Hansford et al., 2004). In the study by Hansford et al. (2004),
these hyperplastic neuroblasts regressed due to apoptotic cell
death in normal and hemizygous transgenic animals, but
frequently progressed to fully transformed neuroblastoma in
homozygous transgenic animals. The similarities and differences
between the murine and zebrafish transgenic models affordcomplementary opportunities to investigate mechanisms under-
lying sympathoadrenal cell transformation within the distinct
anatomical locations that comprise the PSNS.
Using the zebrafish model, we now show that expression of
aberrantly activated ALK potentiates the oncogenic effects of
MYCN by blocking the apoptotic death of MYCN-overexpress-
ing sympathoadrenal neuroblasts. The death of these cells
occurs within a well-defined developmental window, 5.5 wpf,
indicating that although overexpression of MYCN causes aber-
rant expansion of these cells from 3 to 5 wpf, it also triggers an
apoptotic response at 5.5 wpf. By monitoring the appearance
ofmore differentiated adrenal chromaffin cell numbers in animalsCancer Cell 21, 362–373, March 20, 2012 ª2012 Elsevier Inc. 369
Figure 7. MYCN Expression Blocks Chromaffin
Cell Differentiation in the Interrenal Gland
Numbers of GFP+/Hu chromaffin cells in the interrenal
gland in DbH, ALK,MYCN, andMYCN;ALK transgenic fish
at 3 weeks (A), 5 weeks (B), and 7 weeks (C). Means of
GFP+/Hu cell numbers were compared by the two-tailed
Wilcoxon signed-rank test.
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MYCN and ALK in Neuroblastoma Pathogenesisof each genotype, we show that these MYCN-overexpressing
neuroblasts fail to differentiate, resulting in reduced numbers
of Hu, TH+, Dbh+ chromaffin cells. The MYCN-induced
apoptotic response in these cells does not seem to result from
the types of constitutive MYC- or MYCN-induced apoptotic
signaling that has been described by others (Fanidi et al.,
1992; Finch et al., 2006; Nilsson and Cleveland, 2003), because
the MYCN-overexpressing immature neuroblasts in our trans-370 Cancer Cell 21, 362–373, March 20, 2012 ª2012 Elsevier Inc.genic fish do not undergo apoptosis during
their expansion to 5 wpf. Rather, the apoptotic
death of these cells appears to result from
a conflict between aberrant proliferative signals
emanating from overexpressed MYCN and
other developmentally timed signals that spec-
ify chromaffin cell fate. Thus, activated ALKprovides a cell survival signal that blunts the apoptotic response
of MYCN-overexpressing neuroblasts at this juncture in devel-
opment, but does not restore the ability of these cells to differen-
tiate. For the 17% of MYCN-only transgenic fish that develop
tumors, it is likely that additional genetic alterations cooperate
with this oncogene to contribute to neuroblastoma transforma-
tion. Nevertheless, we did not detect somatic missense muta-
tions within the tyrosine kinase domain of the zebrafish alkFigure 8. ALK Inhibits a Developmentally-Timed
Apoptotic Response Triggered by MYCN Overex-
pression in the Interrenal Gland
(A) Numbers of Hu+ interrenal gland cells in the DbH, ALK,
MYCN, and MYCN;ALK fish at 5.5 wpf. Means of Hu+ cell
numbers were compared by the two-tailed Wilcoxon
signed-rank test.
(B) Numbers of apoptotic Hu+ interrenal gland cells in the
DbH, ALK, MYCN, and MYCN;ALK fish at 5.5 wpf. The
numbers of transgenic fish at 5.5 wpf with apoptotic Hu+
cells in the interrenal gland were compared by two-tailed
Fisher exact test.
(C) Sagittal sections through the interrenal gland in MYCN
(top panels) and MYCN;ALK (bottom panels) transgenic
fish at 5.5 wpf (dorsal up, anterior left). Hu, green;
activated Caspase-3, red. Hu+, activated Caspase-3+
apoptotic cells were detected in the MYCN transgenic fish
(arrowheads). Dotted lines indicate the head kidney (HK)
boundary. Scale bars represent 10 mm. See also Fig-
ure S7.
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capsase-8 expression, which has been implicated in the patho-
genesis of human neuroblastoma with MYCN amplification.
Thus, mutations or epigenetic events that activate prosurvival
pathways other than those mediated by alk activation or
capsase-8 loss of function appear to interact withMYCN overex-
pression in these tumors.
The mutant ALK (F1174L) gene that we expressed in our
zebrafishmodel has not been observed in the germline of human
patients with familial neuroblastoma. This suggests that it may
generate signals that are incompatible with normal human
embryogenesis, making it more potent than the R1275Q muta-
tion, the most common heritable mutation in familial neuroblas-
toma. In our transgenic zebrafish model, the ALK (F1174L)
mutation is tolerated in the germline, presumably because it is
driven in a tissue-specific manner in sympathoadrenal cells by
the dbh promoter. In our model system, overexpression of
MYCN is required for the development of neuroblastoma and
activated ALK expression is not sufficient, even though germline
mutations of ALK can function as an initiating event in human
neuroblastoma, and these tumors may or may not have MYCN
amplification (Mosse´ et al., 2008). Further study in the zebrafish
model will be required to determine whether mutational events
other than MYCN overexpression can cooperate with activated
ALK to induce neuroblastoma.
The potent anti-apoptotic effect of activated ALK expression
combined with MYCN overexpression might be expected to
mediate greater resistance to drug-induced apoptosis and
a poorer outcome for patients whose tumors have both amplified
MYCN and an activating ALK mutation. This prediction gains
support from a recent meta-analysis of ALK mutations in child-
hood neuroblastoma with MYCN amplification, which showed
that themutantALK (F1174L) gene is expressed in a high propor-
tion of childhood tumors with MYCN amplification, and that
these children have an especially poor outcome (De Brouwer
et al., 2010). A new ALK small molecule inhibitor, crizotinib
(PF-02341066), has produced encouraging results in a recently
completed phase II trial for patients with non-small-cell lung
cancer that harbors activating ALK rearrangements, including
EML4-ALK or RANBP2-ALK (Butrynski et al., 2010; Kwak
et al., 2010; Sasaki et al., 2010), and has been approved by the
FDA for use in patients with such tumors. A phase I trial of the
same inhibitor was recently initiated in childrenwith solid tumors,
including those with neuroblastoma harboring either mutated or
amplifiedALK. Despite these advances, a recent report indicates
that the ALK (F1174L) mutation confers resistance to crizotinib
(Sasaki et al., 2010), which will likely interfere with the activity
of this drug against neuroblastomas harboring this mutation.
We suggest that the zebrafish model described in this article
will provide a useful platform for testing alternative small mole-
cule inhibitors of F1174L-activated ALK, or key targets within
its downstream pathways, to improve the treatment of this
aggressive form of childhood neuroblastoma.EXPERIMENTAL PROCEDURES
Zebrafish
Zebrafish were the AB background strain. Embryos were staged according to
Kimmel et al. (1995). All zebrafish studies andmaintenance of the animals werein accord with Dana-Farber Cancer Institute IACUC-approved protocol
#02-107.
DNA Constructs for Transgenesis
The 5.2-kb promoter region of the dbh gene was amplified by PCR from
a zebrafish BAC clone and subcloned into vectors to drive the expression
of several genes, including Tg(dbh:EGFP), Tg(dbh:EGFP-MYCN), and
Tg(dbh:EGFP;dbh:ALKF1174L) in tissues normally expressing the dbh gene.
Embryos were injected with these DNA constructs at the one-cell stage and
grown to adulthood. Fin clips from the offspring were genotyped for the stable
integration and germline transmission of the transgenes. The Tg(dbh:EGFP),
Tg(dbh:EGFP-MYCN), and Tg(dbh:EGFP;dbh:ALKF1174L) zebrafish lines are
designated the ‘‘DbH,’’ ‘‘MYCN,’’ and ‘‘ALK’’ transgenic line in this article,
respectively.
Tumor Watch of Transgenic Fish
MYCN and ALK heterozygous transgenic fish were crossed, and offspring
were screened every 2 weeks starting from 5 wpf for fluorescent EGFP-
expressing cell masses indicative of tumors. In addition, for Figure 3B, either
activated human ALK or wild-type human ALK (ALKWT) were overexpressed
in MYCN fish as mosaics by coinjecting the following constructs into the
one-cell stage of MYCN transgenic and control embryos: (1) dbh-ALKF1174L
with dbh-mCherry; (2) dbh-ALKWT with dbh-mCherry; or (3) dbh-mCherry
alone. The primary injected embryos were raised and monitored for the onset
of tumorigenesis as described above. Fish with tumors were separated and
analyzed further by H&E staining and immunohistochemical assays.
RNA In Situ Hybridization, Cryosectioning, Paraffin Sectioning, and
Immunostaining
RNA in situ hybridization assays were performed according to Thisse and
Thisse (Thisse and Thisse, 2008). Constructs for making RNA probes to detect
dbh, th, phox2b, and tfap2a expression have been described (Stewart et al.,
2006). Fish were fixed with 4% paraformaldehyde and embedded in agar/
sucrose or paraffin blocks for cryosectioning or paraffin sectioning, respec-
tively. Sections were immunostained by conventional protocols (Macdonald,
1999) using antibodies against GFP, TH, Hu, Synaptophysin, and ALK.
Electron Microscopy and Imaging
Transmission electron microscopy (TEM) of tumor cells was carried out at the
Harvard Medical School EM Facility with a Tecnai G2 Spirit BioTWIN scope
equipped with an AMT 2k CCD camera. A Zeiss LSM 510 META confocal
microscope and Leica SP5X Laser Scanning Confocal Microscope were
used to capture fluorescent images at high magnification, and a Leica M420
stereoscopic microscope captured bright field and low-magnification fluores-
cent images. Images were processed with Leica LAS AF Lite, Improvision
Openlab v5 and Adobe Photoshop software.
Additionalmethodsarepresented inSupplementalExperimentalProcedures.
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